Summary/transcript
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
The primary endpoint was PFS and the researchers observed a PFS benefit that they think is “clinically relevant and statistically significant,” as Dr Toni Choueiri of the Dana-Farber Cancer Institute highlights. Further, there was a 31% decrease in risk of progression of death. Also, the secondary endpoint, response rate, was higher and more significant with cabozantinib. Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.
The side effects were similar in both arms and in our interview, Dr Choueiri poses the question if cabozantinib could become the next first-line option after sunitinib, which was the standard and most used first-line agent for ten years. He believes that cabozantinib could become the next first-line option and therefore “it is very possible that this study will change how we treat frontline renal cell cancer”.
If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact either
Stephen Dunn or
Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.